These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32636317)

  • 21. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
    Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
    Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular imaging of T cell co-regulator factor B7-H3 with
    Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
    Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical study and first-in-human imaging of [
    Liu L; Zhong J; Zhang Z; Ye X; Wang X; Liu S; Zhang Z
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2012-2022. PubMed ID: 38326656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
    Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
    Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
    Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin α
    Liu K; Jiang T; Rao W; Chen B; Yin X; Xu P; Hu S
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1544-1557. PubMed ID: 38276986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro and In Vivo Characterization of
    Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging.
    Kessel K; Seifert R; Weckesser M; Boegemann M; Huss S; Kratochwil C; Haberkorn U; Giesel F; Rahbar K
    Ann Nucl Med; 2022 Mar; 36(3):293-301. PubMed ID: 34854061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolabeling of PSMA-617 with
    Imura R; Ozeki AN; Shida N; Kobayashi M; Ida H; Wada Y; Akimitsu N; Kumakura Y
    Nucl Med Biol; 2022; 106-107():21-28. PubMed ID: 34998216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.
    Sharma SK; Sevak KK; Monette S; Carlin SD; Knight JC; Wuest FR; Sala E; Zeglis BM; Lewis JS
    J Nucl Med; 2016 May; 57(5):771-6. PubMed ID: 26837339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.
    Laverman P; van der Geest T; Terry SY; Gerrits D; Walgreen B; Helsen MM; Nayak TK; Freimoser-Grundschober A; Waldhauer I; Hosse RJ; Moessner E; Umana P; Klein C; Oyen WJ; Koenders MI; Boerman OC
    J Nucl Med; 2015 May; 56(5):778-83. PubMed ID: 25858044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Preclinical Evaluation of Three Novel
    Verena A; Zhang Z; Kuo HT; Merkens H; Zeisler J; Wilson R; Bendre S; Wong AAWL; Bénard F; Lin KS
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
    Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
    Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
    Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [
    Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.